Marc Recht

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Cooley advised Exscientia, a clinical-stage pharmatech company, on its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion. Lawyers Claire Keast-Butler and Tom Goodman led the Cooley team advising Exscientia.

Cooley advised the underwriters on Talaris Therapeutics' $150 million initial public offering of 8,825,000 shares of common stock. Morgan Stanley, SVB Leerink, Evercore Groupand Guggenheim Securitiesacted as joint book-running managers for the offering. Talaris Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol TALS, is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation. Partners Richard Segal, Marc Recht and Div Gupta led the Cooley team.

Cooley advised Celularity, a clinical-stage biotechnology company developing off-the-shelf allogeneic therapies derived from the postpartum human placenta, on its agreement to become a public company by merging with GX Acquisition Corp., a special purpose acquisition company. Upon closing of the transaction, which is expected in Q2, GX will be renamed Celularity, and its common stock and warrants are anticipated to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” Yvan-Claude Pierre, Marc Recht, Kevin Cooper and Marianne Sarrazin led the Cooley team advising Celularity on the transaction.

Read more